Abstract
Kidney transplantation (KT), as a modality of renal replacement therapy (RRT), has been shown to be both economically and functionally superior to dialysis for the treatment of end-stage renal disease (ESRD). Progress in KT is limited by two major barriers: a) a chronic and burgeoning shortage of transplantable organs and b) the need for chronic immunosuppression following transplantation. Although ground-breaking advances in transplant immunology have improved patient survival and graft durability, a new pathway of innovation is needed in order to overcome current obstacles. Regenerative medicine (RM) holds the potential to shift the paradigm in RRT, through organ bioengineering. Manufactured organs represent a potentially inexhaustible source of transplantable grafts that would bypass the need for immunosuppressive drugs by using autologous cells to repopulate extracellular matrix (ECM) scaffolds. This overview discusses the current status of renal transplantation while reviewing the most promising innovations in RM therapy as applied to RRT.
| Original language | English |
|---|---|
| Pages (from-to) | 169-182 |
| Number of pages | 14 |
| Journal | Expert Review of Clinical Immunology |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2016 |
Fingerprint
Keywords
- Bioengineering
- Decellularization
- Extracellular matrix
- Kidney transplantation
- Regenerative medicine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Kidney transplantation, bioengineering and regeneration : An originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair. / Rogers, Jeffrey; Katari, Ravi; Gifford, Sheyna; Tamburrini, Riccardo; Edgar, Lauren; Voigt, Marcia R.; Murphy, Sean V.; Igel, Daniel; Mancone, Sara; Callese, Tyler; Colucci, Nicola; Mirzazadeh, Majid; Peloso, Andrea; Zambon, Joao Paulo; Farney, Alan C.; Stratta, Robert J.; Orlando, Giuseppe.
In: Expert Review of Clinical Immunology, Vol. 12, No. 2, 01.02.2016, p. 169-182.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Kidney transplantation, bioengineering and regeneration
T2 - An originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair
AU - Rogers, Jeffrey
AU - Katari, Ravi
AU - Gifford, Sheyna
AU - Tamburrini, Riccardo
AU - Edgar, Lauren
AU - Voigt, Marcia R.
AU - Murphy, Sean V.
AU - Igel, Daniel
AU - Mancone, Sara
AU - Callese, Tyler
AU - Colucci, Nicola
AU - Mirzazadeh, Majid
AU - Peloso, Andrea
AU - Zambon, Joao Paulo
AU - Farney, Alan C.
AU - Stratta, Robert J.
AU - Orlando, Giuseppe
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Kidney transplantation (KT), as a modality of renal replacement therapy (RRT), has been shown to be both economically and functionally superior to dialysis for the treatment of end-stage renal disease (ESRD). Progress in KT is limited by two major barriers: a) a chronic and burgeoning shortage of transplantable organs and b) the need for chronic immunosuppression following transplantation. Although ground-breaking advances in transplant immunology have improved patient survival and graft durability, a new pathway of innovation is needed in order to overcome current obstacles. Regenerative medicine (RM) holds the potential to shift the paradigm in RRT, through organ bioengineering. Manufactured organs represent a potentially inexhaustible source of transplantable grafts that would bypass the need for immunosuppressive drugs by using autologous cells to repopulate extracellular matrix (ECM) scaffolds. This overview discusses the current status of renal transplantation while reviewing the most promising innovations in RM therapy as applied to RRT.
AB - Kidney transplantation (KT), as a modality of renal replacement therapy (RRT), has been shown to be both economically and functionally superior to dialysis for the treatment of end-stage renal disease (ESRD). Progress in KT is limited by two major barriers: a) a chronic and burgeoning shortage of transplantable organs and b) the need for chronic immunosuppression following transplantation. Although ground-breaking advances in transplant immunology have improved patient survival and graft durability, a new pathway of innovation is needed in order to overcome current obstacles. Regenerative medicine (RM) holds the potential to shift the paradigm in RRT, through organ bioengineering. Manufactured organs represent a potentially inexhaustible source of transplantable grafts that would bypass the need for immunosuppressive drugs by using autologous cells to repopulate extracellular matrix (ECM) scaffolds. This overview discusses the current status of renal transplantation while reviewing the most promising innovations in RM therapy as applied to RRT.
KW - Bioengineering
KW - Decellularization
KW - Extracellular matrix
KW - Kidney transplantation
KW - Regenerative medicine
UR - http://www.scopus.com/inward/record.url?scp=84957427028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957427028&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2016.1112268
DO - 10.1586/1744666X.2016.1112268
M3 - Article
AN - SCOPUS:84957427028
VL - 12
SP - 169
EP - 182
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 2
ER -